DK3033102T4 - Peptidkonjugerede partikler - Google Patents
Peptidkonjugerede partikler Download PDFInfo
- Publication number
- DK3033102T4 DK3033102T4 DK14836306.2T DK14836306T DK3033102T4 DK 3033102 T4 DK3033102 T4 DK 3033102T4 DK 14836306 T DK14836306 T DK 14836306T DK 3033102 T4 DK3033102 T4 DK 3033102T4
- Authority
- DK
- Denmark
- Prior art keywords
- peptide conjugated
- conjugated particles
- particles
- peptide
- conjugated
- Prior art date
Links
- 239000002245 particle Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361865389P | 2013-08-13 | 2013-08-13 | |
US201361869279P | 2013-08-23 | 2013-08-23 | |
US201361887112P | 2013-10-04 | 2013-10-04 | |
PCT/US2014/050962 WO2015023796A2 (en) | 2013-08-13 | 2014-08-13 | Peptide conjugated particles |
Publications (2)
Publication Number | Publication Date |
---|---|
DK3033102T3 DK3033102T3 (da) | 2019-12-16 |
DK3033102T4 true DK3033102T4 (da) | 2024-02-26 |
Family
ID=52468804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14836306.2T DK3033102T4 (da) | 2013-08-13 | 2014-08-13 | Peptidkonjugerede partikler |
Country Status (24)
Country | Link |
---|---|
US (9) | US9616113B2 (da) |
EP (2) | EP3033102B2 (da) |
JP (4) | JP6553033B2 (da) |
KR (5) | KR20160042079A (da) |
CN (2) | CN105555301B (da) |
AU (4) | AU2014306603B2 (da) |
BR (1) | BR112016003084A2 (da) |
CA (1) | CA2918823A1 (da) |
CY (1) | CY1122558T1 (da) |
DK (1) | DK3033102T4 (da) |
ES (1) | ES2762187T3 (da) |
FI (1) | FI3033102T4 (da) |
HR (1) | HRP20192270T4 (da) |
HU (1) | HUE047329T2 (da) |
IL (3) | IL292567A (da) |
LT (1) | LT3033102T (da) |
ME (1) | ME03590B (da) |
MX (5) | MX2016001931A (da) |
PL (1) | PL3033102T5 (da) |
PT (1) | PT3033102T (da) |
RS (1) | RS59801B2 (da) |
RU (1) | RU2685186C2 (da) |
SI (1) | SI3033102T2 (da) |
WO (1) | WO2015023796A2 (da) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011325966B2 (en) | 2010-11-12 | 2016-09-29 | Oncour Pharma, Inc. | Modified immune-modulating particles |
EP2841098A4 (en) | 2012-04-23 | 2016-03-02 | Allertein Therapeutics Llc | NANOPARTICLES FOR THE TREATMENT OF ALLERGIES |
PL2863942T3 (pl) | 2012-06-21 | 2019-12-31 | Northwestern University | Cząstki sprzężone z peptydem |
JP6725413B2 (ja) | 2013-03-13 | 2020-07-15 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 炎症の治療のための免疫修飾粒子 |
KR102233251B1 (ko) | 2013-04-03 | 2021-03-26 | 엔-폴드 엘엘씨 | 신규 나노입자 조성물 |
BR112016003084A2 (pt) | 2013-08-13 | 2017-09-12 | Univ Northwestern | partículas conjugadas com peptídeo |
EP4299058A3 (en) | 2014-06-24 | 2024-03-27 | The Trustees of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
EP3095440B1 (en) * | 2015-05-19 | 2020-01-15 | PLS-Design GmbH | Antigen-specific immunotherapy using tolerizing liposomes |
BR112018006263A2 (pt) | 2015-10-02 | 2018-10-16 | Memorial Sloan Kettering Cancer Center | inibidor de tonsl, molécula pequena, uso de uma molécula pequena ou de um inibidor, cristal tridimensional, métodos para selecionar ou desenhar uma molécula pequena, para identificar um inibidor de ligação de ard de tonsl à histona h4, para predizer o efeito de inibição de tonsl e para identificar um inibidor de tonsl e/ou determinar o efeito inibitório de um inibidor putativo de tonsl, sequência de polinucleotídeo ou sequência de aminoácidos isolada, e, polipeptídeo mutante de tonsl. |
AU2016378743A1 (en) * | 2015-12-22 | 2018-08-02 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
JP7194593B2 (ja) | 2015-12-23 | 2022-12-22 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 共有ポリマー抗原コンジュゲート化粒子 |
IL260296B2 (en) * | 2016-01-04 | 2024-01-01 | Cour Pharmaceuticals Dev Company Inc | Particles thermalize fusion proteins containing associated epitopes |
JP2019504895A (ja) * | 2016-02-09 | 2019-02-21 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | スギ花粉エピトープを封入するtimp(組織性メタロプロテアーゼ阻害因子) |
WO2017143346A1 (en) | 2016-02-18 | 2017-08-24 | Cour Pharmaceuticals Development Company, Inc. | Process for the preparation of tolerizing immune-modulating particles |
WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
CN111867565A (zh) | 2018-02-08 | 2020-10-30 | 库尔制药发展公司股份有限公司 | 使用耐受颗粒治疗乳糜泻 |
US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
WO2020082090A1 (en) | 2018-10-19 | 2020-04-23 | The Regents Of The University Of Michigan | Method for monitoring autoimmune disease |
JP2022527647A (ja) * | 2019-04-05 | 2022-06-02 | エーエスピー ヘルス インク. | 流体サンプル分配システムおよび方法における消耗部品 |
CN110317255B (zh) * | 2019-07-19 | 2020-07-31 | 北京工商大学 | αs1-酪蛋白的抗原表位制备得到的单抗及牛乳过敏原检测方法 |
EP4021490A4 (en) * | 2019-08-30 | 2023-10-25 | Universidad De Chile | AUTOANTIGEN PEPTIDES (CALVICIFIV), PRESENTED BY TOLEROGENED DENTRIC CELLS, FOR THE PERSONALIZED TREATMENT OF RHEUMATOID ARTHRITIS |
GB201913408D0 (en) * | 2019-09-17 | 2019-10-30 | King S College London | Proinsulin peptides for type 1 diabetes |
US20230026969A1 (en) * | 2019-12-03 | 2023-01-26 | China Medical University | Oligopeptide, Testing Kit Thereof And Medical Composition Thereof |
WO2021155281A1 (en) * | 2020-01-31 | 2021-08-05 | Applied Molecular Transport Inc. | Compositions and methods for treatment of celiac disease |
EP4121451A4 (en) * | 2020-03-20 | 2024-04-10 | Univ Monash | COMPOSITIONS AND METHODS OF TREATMENT OF LUPUS |
ES2963003T3 (es) * | 2020-10-27 | 2024-03-22 | Elucida Oncology Inc | Conjugados de nanopartículas y fármacos dirigidos a receptor de folato y usos de los mismos |
CA3215545A1 (en) | 2021-04-16 | 2022-10-20 | John PUISIS | Method of tracking maintenance of immunological tolerance |
CA3216867A1 (en) * | 2021-04-16 | 2022-10-20 | Cour Pharmaceuticals Development Company Inc. | Treatment of peanut allergy with tolerizing nanoparticles |
AU2022371668A1 (en) | 2021-10-21 | 2024-05-09 | Cour Pharmaceuticals Development Company Inc. | Treatment of primary biliary cholangitis (pbc) with tolerizing nanoparticles |
CN113908256B (zh) * | 2021-11-26 | 2023-05-26 | 中国农业科学院兰州兽医研究所 | Lancl1蛋白在制备抗病毒药物中的应用 |
CN114773434B (zh) * | 2022-03-17 | 2024-04-05 | 南京市妇幼保健院 | 一种用于激活原始卵泡从而治疗或辅助治疗卵巢早衰的多肽pfap1及其应用 |
TW202400801A (zh) | 2022-04-29 | 2024-01-01 | 美商庫爾製藥發展公司股份有限公司 | 用於克服治療性載體及蛋白質之免疫原性之耐受性免疫修飾奈米粒子 |
GB202211696D0 (en) * | 2022-08-10 | 2022-09-21 | Univ London Queen Mary | Peptides and method |
WO2024072751A1 (en) * | 2022-09-26 | 2024-04-04 | The Methodist Hospital | Microparticle formulations for intravenous therapy and methods for their manufacture and use |
WO2024086706A1 (en) | 2022-10-19 | 2024-04-25 | Cour Pharmaceuticals Development Company Inc. | Treatment of peanut allergy with tolerizing nanoparticles |
WO2024094562A1 (en) * | 2022-11-01 | 2024-05-10 | Universität Zürich | Novel mbp peptides and their use in the treatment of multiple sclerosis |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3512940A (en) | 1968-12-30 | 1970-05-19 | Justin J Shapiro | Test tube filter device |
GB8311730D0 (en) | 1983-04-29 | 1983-06-02 | Bagshawe K D | Handling of reaction mixtures |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4990253A (en) | 1988-01-25 | 1991-02-05 | Abbott Laboratories | Fluid sample filtration device |
US5358690A (en) | 1989-01-10 | 1994-10-25 | Lamina, Ltd. | Environmental sample collection and membrane testing device |
DE9013914U1 (da) | 1990-10-05 | 1991-02-14 | Walter Sarstedt Geraete Und Verbrauchsmaterial Fuer Medizin Und Wissenschaft, 5223 Nuembrecht, De | |
ATE228373T1 (de) | 1992-02-28 | 2002-12-15 | Autoimmune Inc | Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
JPH06157592A (ja) | 1992-11-24 | 1994-06-03 | Hitachi Chem Co Ltd | ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−1抗体の製造方法 |
CA2164326A1 (en) | 1993-06-02 | 1994-12-08 | Wayne Robert Thomas | Cryptic peptides for use in inducing immunologic tolerance |
US5833860A (en) | 1995-08-28 | 1998-11-10 | Millipore Investment Holdings Limited | Centrifugal adsorptive sample preparation device and method |
US5804201A (en) | 1996-03-11 | 1998-09-08 | The Rockefeller University | Immunomodulatory peptides of vespid antigen 5 |
JP4085341B2 (ja) | 1997-03-31 | 2008-05-14 | ザ、リージエンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | 開いたポアの生分解性マトリックス |
US7427602B1 (en) | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
WO2001012222A1 (en) | 1999-08-18 | 2001-02-22 | Kim Ho Youn | Immunological tolerance-induction agent |
US20010031262A1 (en) * | 1999-12-06 | 2001-10-18 | Michael Caplan | Controlled delivery of antigens |
CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
EP1311549A2 (en) | 2000-08-22 | 2003-05-21 | Micromet AG | Composition for the elimination of autoreactive b-cells |
US7029697B2 (en) | 2001-02-14 | 2006-04-18 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
US6890556B1 (en) | 2001-02-14 | 2005-05-10 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
US20020187147A1 (en) * | 2001-02-15 | 2002-12-12 | City Of Hope | Antigen specific recombinant MHC class II molecules and methods of use |
CA2465779A1 (en) | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery |
PT1487485E (pt) | 2002-03-19 | 2011-03-11 | Powderject Res Ltd | Adjuvantes de imidazoquinolina para vacinas de adn |
WO2003092654A1 (en) | 2002-05-02 | 2003-11-13 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
JP5068931B2 (ja) | 2002-07-12 | 2012-11-07 | ザ ジョンズ ホプキンス ユニバーシティー | 独自のクローン形質のリンパ球受容体に結合する試薬および方法 |
US7465463B2 (en) | 2002-09-04 | 2008-12-16 | Polyheal, Ltd. | Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues |
US20060189554A1 (en) * | 2002-09-24 | 2006-08-24 | Russell Mumper | Nanoparticle-Based vaccine delivery system containing adjuvant |
WO2005000272A1 (en) * | 2003-06-04 | 2005-01-06 | Isis Pharmaceuticals, Inc. | Long-circulating liposomal compositions |
US20060051407A1 (en) | 2003-06-27 | 2006-03-09 | Yoram Richter | Method of treating ischemia-reperfusion injury |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
WO2005015160A2 (en) | 2003-08-07 | 2005-02-17 | The Children's Hospital Of Philadelphia | Functionalized polymeric colloids |
US8198020B2 (en) | 2003-08-22 | 2012-06-12 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
WO2005020933A2 (en) | 2003-09-02 | 2005-03-10 | University Of South Florida | Nanoparticles for drug-delivery |
AU2004289210B2 (en) | 2003-11-05 | 2010-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
CN101023622B (zh) | 2004-04-02 | 2010-12-08 | 捷讯研究有限公司 | 配置和供应无线手持设备 |
US7846466B2 (en) | 2004-06-10 | 2010-12-07 | Northwestern University | Biodegradable scaffolds and uses thereof |
JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
EP1846446B1 (en) | 2005-02-02 | 2013-06-26 | Novo Nordisk A/S | Insulin derivatives |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US20110182805A1 (en) | 2005-06-17 | 2011-07-28 | Desimone Joseph M | Nanoparticle fabrication methods, systems, and materials |
CN101213226A (zh) * | 2005-07-01 | 2008-07-02 | 霍夫曼-拉罗奇有限公司 | 羧基化胶乳粒子 |
US20070014752A1 (en) | 2005-07-08 | 2007-01-18 | Krishnendu Roy | Surface functionalization of polymeric materials |
GB0514262D0 (en) * | 2005-07-12 | 2005-08-17 | Renovo Ltd | Promotion of epithelial regeneration |
US20070041934A1 (en) | 2005-08-12 | 2007-02-22 | Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
CA2633380A1 (en) * | 2005-12-16 | 2007-07-05 | University Of Kansas | Nanoclusters for delivery of therapeutics |
WO2007087341A2 (en) | 2006-01-25 | 2007-08-02 | The Board Of Trustees Of The University Of Illinois | Tolerogenic biodegradable artificial antigen presenting system |
WO2007094003A2 (en) * | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
RU2008139299A (ru) | 2006-03-02 | 2010-04-10 | СиБАЙО ЛИМИТЕД (AU) | Регуляция иммунных ответов посредством модулирования функции антигенпредставляющих клеток |
AU2007309727A1 (en) * | 2006-04-11 | 2008-05-02 | Albany College Of Pharmacy And Health Sciences | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
JP2009544750A (ja) * | 2006-07-28 | 2009-12-17 | ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ | 治療 |
CA2702340C (en) * | 2006-10-12 | 2014-12-16 | The University Of Queensland | Compositions and methods for modulating immune responses |
US20090214474A1 (en) | 2006-11-01 | 2009-08-27 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
KR101489830B1 (ko) | 2006-12-18 | 2015-02-04 | 콜로로삐아 이탈리아 에스.피.에이 | 발열요법에 적용하기 위한 자성 나노 입자, 그의 제조 및 약리 적용을 갖는 구조체에의 용도 |
DK2131856T3 (da) | 2007-03-07 | 2014-12-15 | Uti Limited Partnership | Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande |
US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
US20110014292A1 (en) | 2007-10-15 | 2011-01-20 | Cooperative Research Centre For Asthma | method of prophylaxis and agents for use therein |
WO2009052561A1 (en) | 2007-10-22 | 2009-04-30 | The Walter And Eliza Hall Institute Of Medical Research | Compositions and methods for manipulating an immune response |
EP2057998A1 (en) | 2007-10-31 | 2009-05-13 | Universitätsklinikum Hamburg-Eppendorf | Use of modified cells for the treatment of multiple sclerosis |
US20090123509A1 (en) * | 2007-11-08 | 2009-05-14 | Cory Berkland | Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds |
US20090238879A1 (en) | 2008-01-24 | 2009-09-24 | Northwestern University | Delivery scaffolds and related methods of use |
JP2009203174A (ja) | 2008-02-26 | 2009-09-10 | Hokkaido Univ | タンパク質−リポソーム複合体を含有するイオントフォレーシス用組成物 |
WO2009131712A2 (en) | 2008-04-25 | 2009-10-29 | Duke University Medical Center | Regulatory b cells and their uses |
US9233110B2 (en) * | 2008-05-09 | 2016-01-12 | Omathanu P. Perumal | Protein nanocarriers for topical delivery |
EP2123261A1 (en) | 2008-05-20 | 2009-11-25 | Stallergenes S.A. | Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance |
US20110206773A1 (en) | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
CA2738855A1 (en) * | 2008-09-29 | 2010-04-01 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
JP5670336B2 (ja) | 2008-10-02 | 2015-02-18 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 全身性炎症の治療のためのポリマー吸着剤の投与 |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
CA3042826A1 (en) | 2008-11-30 | 2010-06-03 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
AU2009326818A1 (en) | 2008-12-11 | 2011-07-07 | The Govenors Of The University Of Alberta | Methods and systems for inducing immunologic tolerance to non-self antigens |
CA2750098A1 (en) | 2009-01-20 | 2010-07-29 | Myelin Repair Foundation, Inc. | Compositions and methods for induction of antigen-specific tolerance |
EP2255831A1 (en) * | 2009-05-25 | 2010-12-01 | Institut Pasteur | Liposome based diepitope constructs |
WO2010138192A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Nanocarriers possessing components with different rates of release |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
JP5486750B2 (ja) | 2009-09-18 | 2014-05-07 | 国立大学法人九州大学 | 金微粒子被覆体とその製造方法、およびその用途 |
RU2448685C2 (ru) * | 2009-11-30 | 2012-04-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза |
US20110135744A1 (en) | 2009-12-03 | 2011-06-09 | The Regents Of The University Of California | Nanoparticle Based Therapy for Dispersing Mucin |
EP2538969A4 (en) * | 2010-02-22 | 2013-11-27 | Liquidia Technologies Inc | VACCINES FROM POLYSACCHARIDE PARTICLES |
US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
WO2011133617A1 (en) * | 2010-04-23 | 2011-10-27 | The Board Of Trustees Of The University Of Illinois | Nano-hybrid delivery system for sequential utilization of passive and active targeting |
AU2011261203B2 (en) | 2010-06-04 | 2014-11-20 | Flow Pharma Inc. | Peptide particle formulation |
EP2576645B1 (en) | 2010-06-04 | 2015-03-18 | Tongji University | Copolymer of pyrene and pyrrole and method of producing the copolymer |
EP2588123A2 (en) | 2010-06-30 | 2013-05-08 | Compugen Ltd. | C1orf32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
AU2011276251B2 (en) * | 2010-07-07 | 2015-02-05 | Artifical Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
EP2598120B1 (en) | 2010-07-31 | 2018-09-05 | The Scripps Research Institute | Compositions and methods for inducing immune tolerance |
WO2012019041A2 (en) | 2010-08-04 | 2012-02-09 | Duke University | Regulatory b cells and their uses |
AU2011325966B2 (en) | 2010-11-12 | 2016-09-29 | Oncour Pharma, Inc. | Modified immune-modulating particles |
WO2012071014A1 (en) | 2010-11-24 | 2012-05-31 | Nanyang Technological University | Method for coating particles with calcium phosphate and particles, microparticles and nanoparticles formed thereof |
US10064406B2 (en) | 2011-01-06 | 2018-09-04 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
ES2712779T3 (es) * | 2011-01-24 | 2019-05-14 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Nanopartículas para la administración dérmica y sistémica de fármacos |
CA3182519A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
US10933129B2 (en) | 2011-07-29 | 2021-03-02 | Selecta Biosciences, Inc. | Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses |
WO2013036294A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses |
EP2811980A4 (en) * | 2012-01-31 | 2015-12-23 | Cerulean Pharma Inc | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS AND METHODS OF USE THEREOF |
WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
PL2863942T3 (pl) | 2012-06-21 | 2019-12-31 | Northwestern University | Cząstki sprzężone z peptydem |
JP6725413B2 (ja) | 2013-03-13 | 2020-07-15 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 炎症の治療のための免疫修飾粒子 |
BR112016003084A2 (pt) | 2013-08-13 | 2017-09-12 | Univ Northwestern | partículas conjugadas com peptídeo |
EP3058082A4 (en) * | 2013-10-18 | 2017-04-26 | ModernaTX, Inc. | Compositions and methods for tolerizing cellular systems |
-
2014
- 2014-08-13 BR BR112016003084A patent/BR112016003084A2/pt not_active Application Discontinuation
- 2014-08-13 AU AU2014306603A patent/AU2014306603B2/en active Active
- 2014-08-13 EP EP14836306.2A patent/EP3033102B2/en active Active
- 2014-08-13 FI FIEP14836306.2T patent/FI3033102T4/fi active
- 2014-08-13 SI SI201431436T patent/SI3033102T2/sl unknown
- 2014-08-13 DK DK14836306.2T patent/DK3033102T4/da active
- 2014-08-13 EP EP19204340.4A patent/EP3650047A1/en active Pending
- 2014-08-13 RU RU2016107998A patent/RU2685186C2/ru active
- 2014-08-13 CA CA2918823A patent/CA2918823A1/en active Pending
- 2014-08-13 CN CN201480046047.XA patent/CN105555301B/zh active Active
- 2014-08-13 HR HRP20192270TT patent/HRP20192270T4/hr unknown
- 2014-08-13 ES ES14836306T patent/ES2762187T3/es active Active
- 2014-08-13 KR KR1020167006265A patent/KR20160042079A/ko not_active Application Discontinuation
- 2014-08-13 JP JP2016534825A patent/JP6553033B2/ja active Active
- 2014-08-13 KR KR1020217024418A patent/KR102485789B1/ko active IP Right Grant
- 2014-08-13 KR KR1020237000033A patent/KR20230008909A/ko not_active Application Discontinuation
- 2014-08-13 KR KR1020227019686A patent/KR20220084202A/ko not_active Application Discontinuation
- 2014-08-13 MX MX2016001931A patent/MX2016001931A/es active IP Right Grant
- 2014-08-13 CN CN202110339093.0A patent/CN113332422A/zh active Pending
- 2014-08-13 KR KR1020247002210A patent/KR20240015725A/ko active Application Filing
- 2014-08-13 LT LTEP14836306.2T patent/LT3033102T/lt unknown
- 2014-08-13 ME MEP-2019-345A patent/ME03590B/me unknown
- 2014-08-13 IL IL292567A patent/IL292567A/en unknown
- 2014-08-13 PL PL14836306.2T patent/PL3033102T5/pl unknown
- 2014-08-13 HU HUE14836306A patent/HUE047329T2/hu unknown
- 2014-08-13 PT PT148363062T patent/PT3033102T/pt unknown
- 2014-08-13 WO PCT/US2014/050962 patent/WO2015023796A2/en active Application Filing
- 2014-08-13 RS RS20191620A patent/RS59801B2/sr unknown
-
2015
- 2015-02-17 US US14/624,463 patent/US9616113B2/en active Active
- 2015-04-03 US US14/678,863 patent/US9522180B2/en active Active
-
2016
- 2016-01-17 IL IL243632A patent/IL243632B/en active IP Right Grant
- 2016-02-12 MX MX2020007079A patent/MX2020007079A/es unknown
- 2016-02-12 MX MX2023000192A patent/MX2023000192A/es unknown
- 2016-02-12 MX MX2023000194A patent/MX2023000194A/es unknown
- 2016-02-12 MX MX2020004799A patent/MX2020004799A/es unknown
- 2016-11-02 US US15/341,935 patent/US10188711B2/en active Active
-
2017
- 2017-03-08 US US15/453,807 patent/US11160851B2/en active Active
-
2018
- 2018-03-15 US US15/922,241 patent/US10617747B2/en active Active
-
2019
- 2019-07-03 JP JP2019124323A patent/JP7007335B2/ja active Active
- 2019-12-10 CY CY20191101296T patent/CY1122558T1/el unknown
-
2020
- 2020-03-25 IL IL273615A patent/IL273615B/en unknown
- 2020-04-13 US US16/847,450 patent/US11129881B2/en active Active
- 2020-04-17 US US16/852,205 patent/US20210000932A1/en not_active Abandoned
- 2020-06-10 AU AU2020203822A patent/AU2020203822B2/en active Active
- 2020-06-10 AU AU2020203824A patent/AU2020203824B2/en active Active
-
2021
- 2021-06-30 US US17/364,351 patent/US11389517B2/en active Active
- 2021-08-16 JP JP2021132266A patent/JP7408604B2/ja active Active
- 2021-09-22 US US17/482,043 patent/US20220008523A1/en active Pending
-
2023
- 2023-08-21 AU AU2023219813A patent/AU2023219813A1/en active Pending
- 2023-12-20 JP JP2023214611A patent/JP2024037982A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273615B (en) | Peptide-conjugated particles | |
CL2015003031A1 (es) | Compuesto peptídico | |
DK3460054T3 (da) | Histidyl-tRNA-syntetase-Fc-konjugater | |
BR112016015105A8 (pt) | conjugados var2csa-droga | |
DK3521423T3 (da) | Manipulerede phenylalaninammoniaklyase-polypeptider | |
DK3041857T3 (da) | Protein a-kromatografi | |
GB201314411D0 (en) | Peptide conjugates | |
PL3061771T3 (pl) | Nowy peptyd o czterech połączonych epitopach dla ctl | |
HK1211596A1 (en) | Peptide | |
DK3004134T3 (da) | Peptid-ligering | |
HK1211595A1 (en) | Peptide | |
HK1198769A1 (en) | Novel peptide | |
DK2983690T3 (da) | Neuropeptid Y-afledte peptider | |
CL2016000836A1 (es) | Composiciones de péptidos nuevas. | |
FR3014440B1 (fr) | Polypeptides entomotoxiques | |
DK3003979T3 (da) | Ikke-oxiderende partikler | |
FI10365U1 (fi) | Kohdistinlaite | |
UY4316S (es) | Diseño celosías | |
ES1091806Y (es) | Escanciador electrico | |
UA28357S (uk) | Шифер | |
FI10180U1 (fi) | Sumutin |